1. Home
  2. CYN vs MDXH Comparison

CYN vs MDXH Comparison

Compare CYN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyngn Inc.

CYN

Cyngn Inc.

HOLD

Current Price

$1.15

Market Cap

22.9M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.42

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYN
MDXH
Founded
2013
2003
Country
United States
Belgium
Employees
62
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
22.9M
21.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CYN
MDXH
Price
$1.15
$0.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
237.8K
786.3K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$368,138.00
N/A
Revenue This Year
$3,359.28
$30.78
Revenue Next Year
$347.47
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.40
52 Week High
$10.04
$5.33

Technical Indicators

Market Signals
Indicator
CYN
MDXH
Relative Strength Index (RSI) 38.14 31.12
Support Level $1.10 N/A
Resistance Level $1.40 $3.79
Average True Range (ATR) 0.09 0.05
MACD -0.01 0.02
Stochastic Oscillator 8.33 15.36

Price Performance

Historical Comparison
CYN
MDXH

About CYN Cyngn Inc.

Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: